Українська Русский English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)
DOI: https://doi.org/10.15407/fz

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor-in-chief: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2019; 65(5): 33-39


PHYSIOLOGICAL SIGNIFICANCE OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN PATIENTS WITH ACUTE FORMS OF CORONARY ARTERY DISEASE

T.I. Gavrilenko, N.O. Ryzhkova, O.M. Parkhomenko, N.V. Dovgan

    NSC « M.D. Strazhesko Institute of Cardiology NAMS of Ukraine, Kyiv, Ukraine
DOI: https://doi.org/10.15407/fz65.05.033

Abstract

A total of 148 patients with acute coronary syndrome, unstable angina and acute myocardial infarction (AMI), and 57 practically healthy individualswere examined. The concentration of vascular endothelial growth factor (VEGF) in the serum of patients with AMI was studied in the dynamics of treatment. Upon admission to hospital, inall groupsof the patients therewereno significant differenceswith the control values. However, in patients with unstable angina the variance was small. At the same time, a large variation of the values (0 -1848.2 pg/ml) was found inpatients with AMI. In this regard, these patients were divided into 3 groups. 1st group included patients (60.4%) with low levels of VEGF <100 pg/ ml,2nd group (21.9%) - with normal - 100 - 300 pg/ml, 3rd group (17.7%) - withhigh –> 300 pg/ml. When comparing 1st and 3rdgroupswith 2nd group,it is necessary to note later admission to hospital, more frequently recorded previously existing AMI and the presenceof concomitant inflammatory diseasesin3rdgroup. Dynamic monitoring of the AMI course during first 7 days of the disease revealed the increase of VEGF in 1st and 2nd groups and the absence of changes in 3rd group. Thus, an increase of VEGF in patients with low and “normal” content of this factor likely indicates its compensatory role for AMI. The absence of this factorgrowth in patients with its initially very high value together with a combination of risk factors may reflects the maximum stress of the compensatory mechanisms and a suboptimalcourse, from a physiological point of view,of AMI hospital period.

Keywords: vascular endothelial growth factor; unstable stenocardia; infarct of myocardium.

References

  1. Bratus VV, Shumakov VA, Talaeva TV. Atherosclerosis, coronary heart disease, acute coronary syndrome: pathogenesis, diagnosis, clinic, treatment. K.: Chetverta hvyla; 2004. [Russian].
  2.  
  3. Gavrilenko TI, Parkhomenko OM, Rizhkova NA, Kozhukhov SM, Yakushko LV. Cytokine profile of mononuclear cells in patients with acute coronary syndrome, accelerated heart failure. Fiziol Zh. 2012;6:23-8. [Ukrainian].
  4.  
  5. Moreno PR, Purushothaman R, Fuster V. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta. Implication for plaque vulnerability. Circulation. 2004;110(14): 2032-38. CrossRef PubMed
  6.  
  7. Ferrara N. Molecular and biological propeties of VEGF. J Mol Med. 1999;77:527-43. CrossRef PubMed
  8.  
  9. Losordo DW, Diommeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease. Part 1: angiogenic cytokines. Circulation. 2004;109:2487-91. CrossRef PubMed
  10.  
  11. Mirzapoiazova T, Kolosova I, Usatyuk PV, Natarajan V, Verin AD. Diverse effects of vascular endothelial growth factor on human pulmonary endothelial barrier and migration. Am J Physiol Lung Cell Mol Physiol. 2006;291:718-24. CrossRef PubMed
  12.  
  13. Rutanen J, Ylä-Herttuala S. VEGF D expression in human atherosclerotic lesions. Cardiovasc Res. 2003;59:971-9. CrossRef  
  14. Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocrin Rev. 2004;25(4):581-611. CrossRef PubMed
  15.  
  16. Smith GA, Fearnley GW, Tomlinson DC, Ponnambalam S. The cellular response to vascular endothelial growth factors requires coordinated signal transduction, trafficking and proteolysis. Biosci Rep. 2015;35(5): e00253. CrossRef PubMed PubMedCentral
  17.  
  18. Marino F, Tozzi M, Schembri L, Ferraro S, Tarallo A, Scanzano A, Legnaro M, Castelli P, Cosentino M. Production of IL-8, VEGF and elastase by circulating and intraplaque neutrophils in patients with carotid atherosclerosis. PLoS One. 2015;10(4): e0124565. CrossRef PubMed PubMedCentral
  19.  
  20. Gavrilenko TI, Ryzhkova NO, Parkhomenko OM. Vascular endothelial growth factor in the clinic of internal diseases and its pathogenetic significance. Ukr Card J. 2011;4:87-95. [Russian].
  21.  
  22. Tsukahara T, Tsukahara R, Haniu H, Murakami-Murofushi K. Cyclic phosphatidic acid inhibits the secretion of vascular endothelial growth factor from diabetic human coronary artery endothelial cells through peroxisome proliferator-activated receptor gamma. Mol Cell Endocrinol. 2015;412:320-9. CrossRef PubMed
  23.  
  24. Kimura K, Hashiguchi T, Deguchi T, Horinouchi S, Uto T, Oku H., Setoyama S, Maruyama I, Osame M, Arimura K. Serum VEGF as a prognostic factor of atherosclerosis. Atherosclerosis. 2007;194:182-8. CrossRef PubMed
  25.  
  26. Tsutsumi Y, Losordo DW. Double face of VEGF. Circulation. 2005;112:1248-50. CrossRef PubMed
  27.  
  28. Ryzhkova NO, Gavrilenko TI, Parkhomenko OM, Kozhukhov SM. Metabolic activity of neutrophilic granulocytes and possible ways of its correction in patients with acute coronary syndrome. Fiziol Zh. 2011;57(2):35-42. [Ukrainian]. CrossRef PubMed
  29.  
  30. Hojo Y, Ikeda U, Zhu Y, Okada M, Ueno S, Arakawa H, Fujikawa H, Katsuki T, Shimada K. Expression of vascular endothelial growth factor in patients with acute myocardial infarction. J Am Coll Cardiol. 2000;35:968-73. CrossRef  
  31. Yang Z, Zou J. Expression of vascular endothelial growth factor in cardiac repair: Signaling mechanisms mediating vascular protective effects. Int J Biol Macromol. 2018;113:179-85. CrossRef PubMed
  32.  
  33. Shurygin M, Shurygina I, Kanya O, Lushnikova EL, Nepomnyashchikh RD. Morphological evaluation of oxidative phosphorylation system in myocardial infarction under conditions of modified vascular endothelial growth factor concentration. Bull Exp Biol Med. 2015;159(3):402-5. CrossRef PubMed
  34.  
  35. Chung HJ, Kim JT, Kim HJ,Katila P,Lee JH,Yang TH,Yang YI, Lee SJ. Epicardial delivery of VEGF and cardiac stem cells guided by 3-dimensional PLLA mat enhancing cardiac regeneration and angiogenesis in acute myocardial infarction. J Control Release. 2015;205:218-30. CrossRef PubMed
  36.  
  37. Zheng W, Seftor EA, Meininger CJ, Hendrix MJ, Tomanek RJ Mechanisms of coronary angiogenesis in response to stretch: role of VEGF and TGFQ. Am J Phisiol Heart Circ Phisiol. 2001;280:909-17. CrossRef PubMed
  38.  
  39. Wang JN, Zhang L, Zheng F, Yang JY, Kong X, Guo LY, Chen L, Huang YZ, Wan Y, Chen SY. VEGF. SDF1 promotes cardiac stem cell mobilization and myocardial repair in the infarcted heart. Cardiovasc Reaseach. 2011;91:402-11. CrossRef PubMed PubMedCentral
  40.  
  41. Zhu Z, Chen AF. Inhibition of PKR impairs angiogenesis through a VEGF pathway. Am J Physiol Endocrinol. 2015;308(6):518-24. CrossRef PubMed

© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2020.